Blood pressure control in patients with chronic kidney disease

Journal of Nippon Medical School

Volumn 79, Issue 2, 2012, Pages 111-114

  Utsumi, Kouichi ^a   Katsura, Ken ichiro ^a   Iino, Yasuhiko ^a   Katayama, Yasuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Angiotensin ii receptor blockers; Angiotensin converting enzyme inhibitors; Cardiovascular disease; Chronic kidney disease; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RAMIPRIL; TELMISARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MONOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84859628168     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.79.111     Document Type: Review

References (14)

1. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
2. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Eng I Med J 1998; 339: 1448-1456.
3. Stevens LA, Greene T, Levey AS: Surrogate end points for clinical trails of kidney disease progression. Clin Am Soc Nephrol 2006; 1: 874-884.
4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. Nakayama M, Metoki H, Terawaki H: Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial transplant 2007; 22: 1910-1915.
6. K/DOQI Clinical practice guideline on hypertension and antihypertensive agents in chronic kidney disease. Am J kidney Dis 2004; 43: S1-S290.
7. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch intern Med 2004; 164: 659-663.
8. Anavekar NS, McMurray JV, Velazquez EJ, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295.
9. Kim S, Izumi Y, Izumiya Y, et al.: Beneficial effects of combined blockade of ACE and AT I receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler Thromb Vasc Biol 2002; 22: 1299-1304.
10. Abe F, Omata K, Yamada M, et al.: Specific direct radioimmunoassay of angiotensin II (A II) in human plasma and the effects of angiotensin converting enzyme (ACE) inhibitor. Immunopharmacology 1999; 44: 199-204.
11. Urata H, Kinoshita A, Misono KS, et al.: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
12. Lewis EJ, Hunsicker LG, Clarke WR: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001; 345: 851-860.
13. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J: Combination therapy with an ACE inhibitor and angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007; 24: 486-493.
14. Yusuf S, Teo KK, Pogue J, et al.: Telmisartan, ramipril, or both in patients at high risk vascular events. N Eng J Med 2008; 358: 1547-1559.